Skip to main content

Health condition

COPD, spirometry, inhalers, pulmonary rehab - and what has changed in 2024 and 2026.

Progressive breathlessness that is treatable at every stage. A short, accessible starting point covering diagnosis, inhalers and the treatments that make the biggest difference.

Looking for the full clinical detail? Read the longer companion at /conditions/chronic-obstructive-pulmonary-disease-copd/.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE NG115, GOLD 2024 and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including triple therapy, dupilumab for eosinophilic COPD and ensifentrine.

Key facts

COPD at a glance.

The essentials in plain English - what COPD is, how it is confirmed and the mainstays of care in the UK today.

  • What it is

    A progressive lung condition with airflow obstruction that is not fully reversible. It groups emphysema and chronic bronchitis under one diagnosis.

  • Main cause

    Long-term smoking is by far the biggest driver. Alpha-1 antitrypsin deficiency, occupational dust and air pollution also matter.

  • How it feels

    Progressive breathlessness on exertion, chronic productive cough, wheeze and frequent chest infections that take a while to shift.

  • How it is confirmed

    Post-bronchodilator spirometry with an FEV1/FVC ratio below 0.7 and limited reversibility. GOLD staging 1 to 4 grades severity.

  • Backbone of care

    Smoking cessation, vaccinations, pulmonary rehabilitation and the right combination of inhalers, escalated to triple therapy where needed.

  • What is new

    Dupilumab was approved for eosinophilic COPD in 2024 and ensifentrine adds a new inhaled option for maintenance.

Why this guide matters

Treatable at every stage.

COPD often creeps up on people. The three things below make more difference than anything else on this page.

  • Smoking cessation still changes the trajectory

    Quitting slows the decline in FEV1 at any stage of COPD. Combined pharmacotherapy plus behavioural support gives the best quit rates.

  • Pulmonary rehab is under-used

    A six to twelve week programme improves breathlessness, exercise capacity and mood more reliably than any single inhaler.

  • Modern therapy has moved on

    Triple therapy in a single inhaler, dupilumab for eosinophilic COPD and ensifentrine mean 2026 care looks very different to 2010.

How the diagnosis is made

From breathlessness to a confirmed plan.

The steps a UK GP or respiratory physician will follow, in order - so you know what to expect and why each one matters.

  1. 01

    Assessing

    History and exposure

    A structured look at smoking pack-years, occupational dust, family history and the pattern of breathlessness and cough.

  2. 02

    Assessing

    mMRC and CAT scores

    The mMRC dyspnoea scale and COPD Assessment Test put numbers on symptoms and quality-of-life impact.

  3. 03

    Assessing

    Post-bronchodilator spirometry

    The confirmatory test. An FEV1/FVC ratio below 0.7 with limited reversibility establishes the diagnosis and GOLD stage.

  4. 04

    Confirming

    Bloods and alpha-1

    Full blood count for eosinophils, alpha-1 antitrypsin level in younger patients or those with limited smoking history.

  5. 05

    Confirming

    HRCT and imaging

    A high-resolution CT (see /tests/private-ct-scan/) maps emphysema pattern and rules out coexisting disease such as bronchiectasis or nodules.

  6. 06

    Preparing

    BODE and exacerbation history

    BODE index combines BMI, obstruction, dyspnoea and exercise. Two or more exacerbations per year signals frequent-exacerbator phenotype.

  7. 07

    Preparing

    Sleep study and comorbidities

    Screen for obstructive sleep apnoea, cardiovascular disease and osteoporosis. These change treatment and prognosis.

Typical timeline: a first visit to a confirmed plan in weeks, not months.

Symptoms

What COPD actually feels like.

The classic combination of progressive breathlessness, chronic cough and wheeze - and the advanced features that shift the plan.

  • Progressive breathlessness

    Shortness of breath on exertion that slowly worsens over months and years. The dominant symptom.

  • Chronic productive cough

    A daily cough with sputum, often worse in the morning. Present for months at a time.

  • Wheeze and chest tightness

    Whistling sounds on expiration and a sensation of tight airways, especially during exertion or infections.

  • Exercise intolerance

    Struggling with hills, stairs and daily tasks that used to be easy. Often adapted to without noticing.

  • Frequent chest infections

    Two or more exacerbations a year needing steroids or antibiotics defines the frequent-exacerbator phenotype.

  • Weight loss and muscle wasting

    A feature of advanced disease. Loss of appetite plus the metabolic cost of breathing drives cachexia.

  • Cor pulmonale

    Right heart strain with ankle swelling, raised JVP and hepatic congestion. A late finding in advanced COPD.

  • Red flag - acute exacerbation

    Sudden worsening of breathlessness, sputum volume or purulence needs same-day medical review and often steroids.

Treatment

How COPD is treated in the UK.

A stepped plan built around smoking cessation, vaccinations and pulmonary rehab, layered with inhalers, oxygen and - where indicated - biologics or bronchoscopic procedures.

  • Smoking cessation

    The single most effective intervention at any stage. Combined pharmacotherapy plus behavioural support gives the best quit rates.

  • Vaccinations

    Annual influenza, pneumococcal, COVID and RSV where eligible. Together they cut exacerbations and hospital admissions.

  • Pulmonary rehabilitation

    A six to twelve week supervised exercise and education programme. See /treatments/pulmonary-rehabilitation-programme/ for the full protocol.

  • Inhaled therapy ladder

    SABA reliever plus LABA or LAMA maintenance. Escalate to LABA plus LAMA, then triple therapy (Trelegy, Trixeo, Trimbow) for frequent exacerbators or high eosinophils.

  • Long-term oxygen and NIV

    LTOT for chronic hypoxaemia and non-invasive ventilation for hypercapnic respiratory failure. See /treatments/non-invasive-ventilation-niv/.

  • Endobronchial valves and LVR

    Bronchoscopic valve placement or surgical lung volume reduction for selected patients with severe emphysema. See /treatments/endobronchial-valves-lvr/.

  • Biologics and ensifentrine

    Dupilumab was approved in 2024 for Type 2 eosinophilic COPD with frequent exacerbations. Ensifentrine adds a novel inhaled maintenance option.

  • Exacerbation and palliative care

    Short-course oral steroids, antibiotics and oxygen for flares. MDT support and palliative input for advanced disease and end-of-life planning.

For the full stepwise inhaler tables, biologic eligibility criteria and end-of-life pathway, see the detailed guide at /conditions/chronic-obstructive-pulmonary-disease-copd/.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, international specialist standards and MHRA licence updates, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or respiratory consultant knows your history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115).

  • GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, 2024 report.

  • MHRA. Dupilumab licence update for eosinophilic COPD, 2024.

  • Asthma and Lung UK. Patient information and support for people living with COPD.

Red flags

When COPD needs urgent attention.

Most COPD care happens in primary care and outpatient clinics. These are the situations that need same-day review or a specialist opinion.

  • Acute severe exacerbation

    Sudden marked breathlessness, cyanosis, drowsiness or confusion needs 999 or urgent hospital assessment.

  • Type 2 respiratory failure

    Rising CO2 causes drowsiness, flapping tremor and headache. Requires non-invasive ventilation in hospital.

  • Haemoptysis

    Coughing blood should never be dismissed as COPD alone. It needs urgent imaging to exclude lung cancer or bronchiectasis.

  • Weight loss and cachexia

    Unintentional weight loss in COPD is a poor prognostic sign and warrants dietetic and MDT input.

  • Cor pulmonale

    Ankle swelling, raised JVP or new right heart strain on ECG needs echocardiography and oxygen assessment.

  • Frequent exacerbations

    Two or more flares a year is a phenotype in its own right. Escalate to triple therapy and consider biologics.

  • Young onset or minimal smoking

    Consider alpha-1 antitrypsin deficiency, occupational exposure or an alternative diagnosis such as bronchiectasis.

  • Pneumothorax

    Sudden pleuritic chest pain with worsening breathlessness in an emphysematous patient. Urgent chest imaging is needed.

  • Depression and social isolation

    Common in advanced COPD and often under-recognised. Screen actively and refer for support.

Living with it

A long-term condition, with a plan you can hold on to.

Four things that move the needle day to day - quitting smoking, moving your body, having a written plan for flare-ups and knowing where to turn for support.

A quiet reminder

Small consistent steps beat one big push.

Short walks, regular inhaler technique and a clear escalation plan - kept up for months - do more than an intense week that does not last.

  1. 01 Stop smoking

    The one thing that changes everything

    Quitting slows decline at every stage. Combined nicotine replacement, varenicline or bupropion plus behavioural support gives the best odds.

  2. 02 Move

    Pulmonary rehab is transformative

    A structured exercise programme improves breathlessness, exercise capacity and mood more than any single inhaler.

  3. 03 Plan

    A written self-management plan

    Know your usual state, your warning signs and what to do. A rescue pack of steroids and antibiotics may be right for some.

  4. 04 Connect

    Asthma and Lung UK

    The national charity offers a helpline, local Breathe Easy groups and clear guidance for patients and families.

Frequently asked

Everything we get asked about COPD.

Quick answers on spirometry, inhalers, dupilumab and how the short and long guides fit together.

  • What is COPD?

    Chronic obstructive pulmonary disease is a progressive lung condition where airflow is obstructed and not fully reversible. It groups emphysema (destruction of alveoli) and chronic bronchitis (chronic productive cough) under a single diagnosis, most often caused by long-term smoking.

  • How is COPD diagnosed?

    The confirmatory test is post-bronchodilator spirometry showing an FEV1/FVC ratio below 0.7 with limited reversibility. Assessment also includes symptom scores (mMRC and CAT), exacerbation history, blood eosinophils, alpha-1 antitrypsin level and often a high-resolution CT scan.

  • What is the difference between this page and the detailed COPD guide?

    This is a short accessible starting point. For the full clinical guide including GOLD staging tables, inhaler specifics and the complete evidence base, see our longer companion page at /conditions/chronic-obstructive-pulmonary-disease-copd/.

  • Which inhalers are used in COPD?

    A short-acting bronchodilator (SABA) as reliever, and maintenance therapy stepped up from LABA or LAMA to LABA plus LAMA, then triple therapy combining LABA, LAMA and inhaled corticosteroid (Trelegy Ellipta, Trixeo Aerosphere, Trimbow) for frequent exacerbators or those with high blood eosinophils.

  • Is there a biologic for COPD?

    Yes. Dupilumab was approved in 2024 for adults with Type 2 eosinophilic COPD and frequent exacerbations despite triple therapy. It is delivered through a specialist biologics clinic. See /treatments/asthma-biologics-clinic/ for how the pathway works.

  • What happens during an exacerbation?

    An acute worsening is treated with increased bronchodilators, a short course of oral steroids (typically prednisolone for five days) and antibiotics if sputum is purulent. Severe exacerbations need controlled oxygen and often non-invasive ventilation in hospital.

Related content

Keep reading.